Trusted by:

clients clients clients clients clients clients clients clients clients clients
Newswise: ASH Presentation: Study Shows That Genetic Mutations Accumulate in Smokers with Myelodysplastic Syndromes and Worsen Outcomes
6-Dec-2024 5:00 PM EST
ASH Presentation: Study Shows That Genetic Mutations Accumulate in Smokers with Myelodysplastic Syndromes and Worsen Outcomes
Sylvester Comprehensive Cancer Center

Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.

Newswise: EMBARGOED: Dozens of Presentations Advance Multiple Myeloma Research at the 2024 American Society for Hematology (ASH) Meeting
6-Dec-2024 5:40 PM EST
EMBARGOED: Dozens of Presentations Advance Multiple Myeloma Research at the 2024 American Society for Hematology (ASH) Meeting
Sylvester Comprehensive Cancer Center

Patients with multiple myeloma are living longer thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center are working to change that, and will present research findings at the 2024 annual meeting of the American Society of Hematology (ASH).

Released: 9-Dec-2024 8:00 PM EST
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
University of Texas MD Anderson Cancer Center

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

Newswise: Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH
9-Dec-2024 7:30 PM EST
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH
Roswell Park Comprehensive Cancer Center

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.

Newswise: Could US-style Summer Holiday Programs Boost Aussie Kids’ Health?
Released: 9-Dec-2024 7:10 PM EST
Could US-style Summer Holiday Programs Boost Aussie Kids’ Health?
University of South Australia

As the school year winds up, thousands of Aussie kids are looking forward to the summer holidays. But hand-in hand with this freedom comes an abundance of screentime, unhealthy snacks, and a lack of routine, and it has the potential to affect children’s physical and mental health.

Newswise: Toxoplasma Gondii Parasite Uses Unconventional Method to Make Proteins for Evasion of Drug Treatment
Released: 9-Dec-2024 6:05 PM EST
Toxoplasma Gondii Parasite Uses Unconventional Method to Make Proteins for Evasion of Drug Treatment
Indiana University

A study sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment.

Released: 9-Dec-2024 5:45 PM EST
ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory Disorder
University of Texas MD Anderson Cancer Center

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Lighting Campus for Hope: A Winter Wonderland of Resilience and Community
Released: 9-Dec-2024 5:00 PM EST
Lighting Campus for Hope: A Winter Wonderland of Resilience and Community
Texas Tech University Health Sciences Center El Paso

More than just a holiday gathering, this free, family-friendly event marked the culmination of a year-long appeal that raised $255,000 to provide 1,350 life-saving cancer screenings in our Borderplex community. Every dollar from event sponsorships will directly support cancer screenings and diagnostics, emphasizing the transformative impact of early detection and care.

Not for public release

This news release is embargoed until 9-Dec-2024 5:00 PM EST Released to reporters: 3-Dec-2024 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 9-Dec-2024 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 9-Dec-2024 5:00 PM EST Released to reporters: 3-Dec-2024 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 9-Dec-2024 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


close
2.0028